Clinical Trials Browser

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer × fluzoparib × Clear all

NCT05656131 2026-03-17

Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Phase 2 Suspended

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer